JP2017518318A - 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 - Google Patents

天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 Download PDF

Info

Publication number
JP2017518318A
JP2017518318A JP2016571256A JP2016571256A JP2017518318A JP 2017518318 A JP2017518318 A JP 2017518318A JP 2016571256 A JP2016571256 A JP 2016571256A JP 2016571256 A JP2016571256 A JP 2016571256A JP 2017518318 A JP2017518318 A JP 2017518318A
Authority
JP
Japan
Prior art keywords
fragment
antibody
seq
sequence
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016571256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518318A5 (enExample
Inventor
ブイ． マイケル ホラーズ，
ブイ． マイケル ホラーズ，
ナーマル バンダ，
ナーマル バンダ，
リュドミラ クーリック，
リュドミラ クーリック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2017518318A publication Critical patent/JP2017518318A/ja
Publication of JP2017518318A5 publication Critical patent/JP2017518318A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016571256A 2014-06-05 2015-06-04 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 Pending JP2017518318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008470P 2014-06-05 2014-06-05
US62/008,470 2014-06-05
PCT/US2015/034270 WO2015187992A2 (en) 2014-06-05 2015-06-04 Map44 polypeptides and constructs based on natural antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171880A Division JP2021006581A (ja) 2014-06-05 2020-10-12 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用

Publications (2)

Publication Number Publication Date
JP2017518318A true JP2017518318A (ja) 2017-07-06
JP2017518318A5 JP2017518318A5 (enExample) 2018-08-02

Family

ID=54767594

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016571256A Pending JP2017518318A (ja) 2014-06-05 2015-06-04 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用
JP2020171880A Pending JP2021006581A (ja) 2014-06-05 2020-10-12 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171880A Pending JP2021006581A (ja) 2014-06-05 2020-10-12 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用

Country Status (8)

Country Link
US (3) US20170209549A1 (enExample)
EP (1) EP3151845A4 (enExample)
JP (2) JP2017518318A (enExample)
CN (1) CN106687123A (enExample)
AU (3) AU2015269348C1 (enExample)
CA (1) CA2951159A1 (enExample)
IL (1) IL249368B (enExample)
WO (1) WO2015187992A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531452A (ja) * 2017-08-15 2020-11-05 オメロス コーポレーション 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
WO2018075484A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
PH12021551398A1 (en) * 2018-12-11 2022-11-07 Q32 Bio Inc Fusion protein constructs for complement associated disease
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
GB2628281A (en) * 2022-01-07 2024-09-18 Jumio Corp Biometric authentication using head-mounted devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508301A (ja) * 2009-10-16 2013-03-07 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
JP2013543380A (ja) * 2010-10-01 2013-12-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド ヒト補体成分ｃ５に結合するポリペプチド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014270A1 (en) * 2006-03-27 2011-01-20 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury and related conditions
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20120122107A1 (en) * 2010-11-16 2012-05-17 Aarhus Universitet Homeostatic multidomain protein, and uses for it
MX381048B (es) * 2012-06-18 2025-04-01 Omeros Corp Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
US11007254B2 (en) * 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508301A (ja) * 2009-10-16 2013-03-07 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
JP2013543380A (ja) * 2010-10-01 2013-12-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド ヒト補体成分ｃ５に結合するポリペプチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 126, JPN6019013245, 2012, pages 2227 - 2235, ISSN: 0004283957 *
MOLECULAR IMMUNOLOGY, vol. 47, JPN6019043860, 2010, pages 2266, ISSN: 0004283958 *
THE JOURNAL OF IMMUNOLOGY, vol. Vol.190, 1 Supplement, JPN6019043861, 2013, pages 131 - 26, ISSN: 0004283959 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020531452A (ja) * 2017-08-15 2020-11-05 オメロス コーポレーション 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法

Also Published As

Publication number Publication date
AU2015269348B2 (en) 2021-03-04
AU2015269348C1 (en) 2021-11-18
CN106687123A (zh) 2017-05-17
US20250000955A1 (en) 2025-01-02
IL249368A0 (en) 2017-02-28
JP2021006581A (ja) 2021-01-21
WO2015187992A2 (en) 2015-12-10
AU2024204307A1 (en) 2024-07-11
US20170209549A1 (en) 2017-07-27
IL249368B (en) 2020-06-30
EP3151845A2 (en) 2017-04-12
CA2951159A1 (en) 2015-12-10
AU2021200908A1 (en) 2021-03-04
EP3151845A4 (en) 2018-01-17
AU2015269348A1 (en) 2016-12-22
WO2015187992A3 (en) 2016-02-25
US20210213110A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US20250000955A1 (en) Map44 polypeptides and constructs based on natural antibodies and uses thereof
AU2019201826B2 (en) Targeting constructs based on natural antibodies and uses thereof
US9815890B2 (en) Antibodies to the C3d fragment of complement component 3
JP6022441B2 (ja) 抗Ｃ５ａ抗体およびその抗体の使用のための方法
US8007798B2 (en) Treatment of complement-associated disorders
US20190002541A1 (en) Modulating the alternative complement pathway
KR20210013091A (ko) 가용성 보체 수용체 1형 변이체 및 이의 용도
US11806389B2 (en) Compositions and methods for treating central nervous system injury
US20250222127A1 (en) Compositions and methods for treating and preventing transplant-associated injury
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
RU2799044C2 (ru) Антитела против фактора d и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200612